TKI safety
EHA Library. Hjorth-Hansen H. 06/14/19; 273674
Henrike Hjorth-Hansen
Contributions
Contributions
Learning Objectives
THIS MANUSCRIPT IS PUBLISHED AS AN OFFICIAL SUPPLEMENT OF HEMASPHERE.
Oliver Hantschel - Chair introduction
Chronic myeloid leukemia (CML) became a paradigm for targeted cancer therapy due to the unprecedented clinical success of the tyrosine kinase inhibitor (TKI) imatinib. Most CML patients in the chronic phase of CML that are treated with imatinib achieve durable remissions and their survival is not different from that of the general population. Still, a fraction of patients is intolerant or resistant to imatinib. For these patients, 4 additional TKIs—dasatinib, nilotinib, bosutinib, and ponatinib—are approved as salvage therapies and subsequently dasatinib, nilotinib, and bosutinib were also approved for first-line therapy. The first paper of this educational session will provide an overview of the current treatment approaches in CML. As the 5 approved TKIs for CML strongly differ in their adverse events profile, the second paper will give an expert summary of transient reversible and potentially irreversible side effect of these TKIs. It will provide guidance how to identify the most efficacious treatment in early disease stages and how to manage side effects. The third paper of the session will review the insights that were obtained from next-generation sequencing (NGS) studies in CML and provide future perspectives of NGS for risk stratification of CML patients.
Learning goals of the article
• To review state-of-the-art treatment approaches in CML with treatment free remission as important goal.
• To improve knowledge on individual TKI toxicity profiles and side effect management.
• To discuss insights from NGS to optimize treatment of CML patients.
Learning goals of the presentation
After attending this lecture, the participant will be able to
• set clear management goals and choose TKI based on the side effect profile of TKI in light of patient characteristics/comorbidities, and
• be aware of common and clinically important side effects of TKIs and how to manage these.
Oliver Hantschel - Chair introduction
Chronic myeloid leukemia (CML) became a paradigm for targeted cancer therapy due to the unprecedented clinical success of the tyrosine kinase inhibitor (TKI) imatinib. Most CML patients in the chronic phase of CML that are treated with imatinib achieve durable remissions and their survival is not different from that of the general population. Still, a fraction of patients is intolerant or resistant to imatinib. For these patients, 4 additional TKIs—dasatinib, nilotinib, bosutinib, and ponatinib—are approved as salvage therapies and subsequently dasatinib, nilotinib, and bosutinib were also approved for first-line therapy. The first paper of this educational session will provide an overview of the current treatment approaches in CML. As the 5 approved TKIs for CML strongly differ in their adverse events profile, the second paper will give an expert summary of transient reversible and potentially irreversible side effect of these TKIs. It will provide guidance how to identify the most efficacious treatment in early disease stages and how to manage side effects. The third paper of the session will review the insights that were obtained from next-generation sequencing (NGS) studies in CML and provide future perspectives of NGS for risk stratification of CML patients.
Learning goals of the article
• To review state-of-the-art treatment approaches in CML with treatment free remission as important goal.
• To improve knowledge on individual TKI toxicity profiles and side effect management.
• To discuss insights from NGS to optimize treatment of CML patients.
Learning goals of the presentation
After attending this lecture, the participant will be able to
• set clear management goals and choose TKI based on the side effect profile of TKI in light of patient characteristics/comorbidities, and
• be aware of common and clinically important side effects of TKIs and how to manage these.
{{ help_message }}
{{filter}}